Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaccinated donor plasma is a blood-derived therapeutic product consisting of plasma collected from individuals who have been vaccinated against SARS-CoV-2. This plasma contains high titers of vaccine-induced neutralizing antibodies and immunoglobulin G (IgG) specifically targeting the viral spike protein. It is used as a form of passive immunotherapy to provide immediate, though temporary, protection or treatment for COVID-19, particularly in immunocompromised patients or those at high risk of severe disease. Clinical evaluation, such as the study by Jiangsu Provincial People's Hospital (ChiCTR2300078690), focuses on the safety, durability of the immune response, and cost-effectiveness of this treatment compared to standard low-titer plasma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vaccinated donor plasma.